About the journal
Current Drug Targets is a journal published by Bentham Science Publishers in Netherlands. It is listed in MEDLINE and PUBMED according to the sources read. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Bentham Science Publishers
- ISSN
- 1389-4501 · 1873-5592
- Country
- Netherlands
- Access
- Not open access / not declared
- Official website
- http://benthamscience.com/journal/index.php?journalid=cdt
Index listings
- MEDLINE · 2000-01-01
- PUBMED · 2011-03-01
- Indexing
- MEDLINE · PUBMED
- APC
- —
- Declared review time (DOAJ)
- —
- Actual review time (measured)
- 86 days received→accepted — computed from PubMed (n=100)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Works in OpenAlex
3503
Last recorded publication year
2026
h-index
138
i10-index
2195
From OpenAlex open data (CC0).
Editorial & policy5
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- Portico
- Norwegian register (HK-dir)— 2026
- Level 1 — approved scholarly channel
- Open references deposited at Crossref
- 73%
- ORCID iDs in current deposits
- 53%
- Enrolled in Crossref Similarity Check
- ✓
- Deposits licence metadata at Crossref
- ✓
Identity & continuity2
- Source type
- journal
- NLM unique ID (PubMed)
- 100960531
Classification(no data)
No data available to the platform for this group
No platform data for: Classification — absence is not a judgment about the journal.
Subject areas
- Computational Drug Discovery Methods
- Computational Drug Discovery Methods
- Cancer Mechanisms and Therapy
- Cancer Mechanisms and Therapy
- Inflammatory Bowel Disease
- Inflammatory Bowel Disease
- Diverse Scientific and Economic Studies
- Diverse Scientific and Economic Studies
Show all subjects (50)
- Nanoparticle-Based Drug Delivery
- Nanoparticle-Based Drug Delivery
- RNA Interference and Gene Delivery
- RNA Interference and Gene Delivery
- 14-3-3 protein interactions
- 14-3-3 protein interactions
- Cholinesterase and Neurodegenerative Diseases
- Cholinesterase and Neurodegenerative Diseases
- MicroRNA in disease regulation
- MicroRNA in disease regulation
- Receptor Mechanisms and Signaling
- Receptor Mechanisms and Signaling
- Cancer Research and Treatment
- Cancer Research and Treatment
- Synthesis and biological activity
- Synthesis and biological activity
- Monoclonal and Polyclonal Antibodies Research
- Monoclonal and Polyclonal Antibodies Research
- Antibiotic Resistance in Bacteria
- Antibiotic Resistance in Bacteria
- Neuroscience and Neuropharmacology Research
- Cancer Research and Treatments
- Cancer Research and Treatments
- Cancer therapeutics and mechanisms
- Neuroscience and Neuropharmacology Research
- Cancer therapeutics and mechanisms
- Cancer, Hypoxia, and Metabolism
- Protease and Inhibitor Mechanisms
- Biochemical and Molecular Research
- Biochemical and Molecular Research
- Protease and Inhibitor Mechanisms
- Inflammatory mediators and NSAID effects
- Cancer, Hypoxia, and Metabolism
- Mitochondrial Function and Pathology
- Mitochondrial Function and Pathology
- Cancer, Lipids, and Metabolism
- Cancer-related Molecular Pathways
- Cytokine Signaling Pathways and Interactions
- Cancer-related Molecular Pathways
- Inflammatory mediators and NSAID effects
- Cancer, Lipids, and Metabolism
- Cytokine Signaling Pathways and Interactions
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ